San Diego Stock Exchange

SEARCH SAN DIEGO STOCKS:

Symbol

ANADYS PHARMACEUTICALS INC

Symbol	Name	Close	Change		Volume	Dayhigh	Daylow
ANDS	Anadys Pharma	2.19	0.03	+ 1.39%	248321.00	2.19	2.10

Exchange	Earningspershare	52-Week High	52-Week Low
NASDAQ N-Mkt	-1.13	8.43	1.44

SourceBook Information

Anadys Pharmaceuticals Inc. is listed in:

• Biomed & Biotech Firms -
• Biomed & Biotech Firms - Publicly Traded -
• Local Publicly Traded Companies -

Contact Information

Company Name

Anadys Pharmaceuticals Inc.

Executives

George Scangos, Chairman

Kleanthis G. Xanthopoulos, CEO/President

Address

3115 Merryfield Row

San Diego, CA 92121

Phone

(858) 530-3600

Fax

(858) 527-1540

E-mail

n/a

Web Page

www.anadyspharma.com

Business Information

Parent Company

n/a

Business Description

A biopharmaceutical company committed to advancing patient care by discovering, developing and commercializing novel small molecule medicines for the treatment of chronic viral infections and bacterial infections.

SIC Code

n/a

Headquarters

San Diego, CA

Local Mailing Address

3115 Merryfield Row, San Diego, CA 92121

Year Established

2000

Year Established in San Diego

2000

Publicly Traded?

Yes

Ticker Symbol

ANDS

Total Number of Employees

83

Number of Local Employees

n/a

Number of Offices Local

n/a

Market Capitalization

$80,589,370

Gross Revenue 2000

wnd

Gross Revenue 2000 Year End

wnd

Gross Revenue 2001

wnd

Gross Revenue 2001 Year End

wnd

Gross Revenue 2002

wnd

Gross Revenue 2002 Year End

wnd

Gross Revenue 2003

$2,000,000

Gross Revenue 2003 Year End

wnd

Gross Revenue 2004

$2,000,000

Gross Revenue 2005 YTD, Local

n/a

Gross Revenue 2007

n/a

Manufacturer

n/a

Fields of Research

Developing medicines in the areas of hepaitis C, oncology

Major Products

Toll-like Receptors, structure based drug design

Major Investors

n/a

Number of Products Approved For Sale

n/a

Patents

n/a

Number of Products In Development

n/a

Strategic Alliances

n/a

Services Offered

n/a

Chief Executive Officer

Kleanthis G. Xanthopoulos

Date CEO Began

May 2000

Total Annual CEO Compensation (salary & bonuses)

$505,000 (FY 2004)

CEO Salary

$330,000 (FY 2004)

CEO Bonuses

$175,000 (FY 2040)

Gross Revenue 2006

n/a

Sales for 2006

n/a

Gross Revenue 2008

n/a

Mission Statement

n/a